InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,062.00
(
-0.10%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.76
(
0.00%
)
Bitcoin
67,269.30
(
0.49%
)
Post# of 20775
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

tencoin

Send PM Follow Ignore
Followers 9
Posts 450
Boards Moderated 0
Alias Born 09/29/2011

tencoin

Re: None

Tuesday, 11/26/2013 9:45:45 AM

Tuesday, November 26, 2013 9:45:45 AM

Post# of 20775
Nov. 26, 2013 (GLOBE NEWSWIRE)

CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease, announced today Richard Margolin, MD, has joined the Company as Vice President, Clinical Development. Dr. Margolin will lead CereSpir's Phase 3 program for CHF 5074, which includes two clinical trials anticipated to begin in 2014, and will report directly to Daniel G. Chain, PhD, Chairman, President and Chief Executive Officer. ........

http://globenewswire.com/news-release/2013/11/26/592577/10059519/en/CereSpir-Incorporated-Appoints-Richard-Margolin-MD-as-Vice-President-Clinical-Development.html

..................................................................................................

I hope that CereSpir bought Intellect, it will be a new and big Pharma in Alzheimer's field ...



















.


Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up